# OnCo record immune-desert-exclusion (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/immune-desert-exclusion/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "immune-desert-exclusion" ;
  schema:name "Cold tumours: immune deserts and exclusion"@en ;
  schema:description "Tumours come in three immune weathers: inflamed (T cells inside, checkpoint drugs work), excluded (T cells stuck at the edge), and desert (no T cells at all). Most common cancers are excluded or desert, and turning them 'hot' is the central problem of immunotherapy."@en ;
  schema:url <https://onco.cc/pathways/immune-desert-exclusion/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Tumor-infiltrating_lymphocytes> ;
  schema:citation <https://doi.org/10.1038/nature21349>, <https://doi.org/10.1038/nature14404> ;
  onco:tag "mechanism", "mechanics-atlas" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/oncolytic-virus/>, <https://onco.cc/technologies/in-situ-vaccination/>, <https://onco.cc/technologies/sting-agonist/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/epigenetic-drugs/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/single-cell-spatial/>, <https://onco.cc/technologies/il12-electroporation/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/fap/>, <https://onco.cc/targets/ezh2/>, <https://onco.cc/targets/csf1r/>, <https://onco.cc/targets/cxcr4/>, <https://onco.cc/targets/pik3ca/> ;
  onco:drugs <https://onco.cc/drugs/talimogene-laherparepvec/>, <https://onco.cc/drugs/vusolimogene-oderparepvec/>, <https://onco.cc/drugs/ivonescimab/>, <https://onco.cc/drugs/adu-s100/>, <https://onco.cc/drugs/tazemetostat/> ;
  onco:pathways <https://onco.cc/pathways/tgf-beta/>, <https://onco.cc/pathways/wnt/>, <https://onco.cc/pathways/cgas-sting/>, <https://onco.cc/pathways/tumor-microenvironment/>, <https://onco.cc/pathways/cancer-immunity-cycle/>, <https://onco.cc/pathways/myeloid-suppression-axis/> ;
  onco:terms <https://onco.cc/terms/cold-vs-hot/>, <https://onco.cc/terms/immune-exclusion/>, <https://onco.cc/terms/tils/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/cps/>, <https://onco.cc/terms/desmoplasia/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-immunotherapy-response/>, <https://onco.cc/bottlenecks/b-tme-immunosuppression/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-chen-nature/>, <https://onco.cc/key-papers/paper-spranger-nature/> .